US20080300213A1 - Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment - Google Patents

Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment Download PDF

Info

Publication number
US20080300213A1
US20080300213A1 US11/632,897 US63289706A US2008300213A1 US 20080300213 A1 US20080300213 A1 US 20080300213A1 US 63289706 A US63289706 A US 63289706A US 2008300213 A1 US2008300213 A1 US 2008300213A1
Authority
US
United States
Prior art keywords
agonist
osteoarthritis
treatment
adenosine
iodobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/632,897
Other languages
English (en)
Inventor
Pnina Fishman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to CAN-FITE BIOPHARMA LTD. reassignment CAN-FITE BIOPHARMA LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FISHMAN, PNINA
Assigned to CAN-FITE BIOPHARMA LTD. reassignment CAN-FITE BIOPHARMA LTD. CORRECTED COVER SHEET TO CORRECT THE EXECUTION DATE, PREVIOUSLY RECORDED AT REEL/FRAME (ASSIGNMENT OF ASSIGNOR'S INTEREST) Assignors: FISHMAN, PNINA
Publication of US20080300213A1 publication Critical patent/US20080300213A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to therapy and in particular to treatment of osteoarthritis.
  • Osteoarthritis known in the past as degenerative arthritis, is the most common form of arthritis. It is a joint disease that occurs after abnormality or damage of joints or without joint damage. The disease involves the deterioration of cartilage in the joints. Over time, the cartilage, covering the ends of bones in a joint, begins to break down and may wear away entirely, and the bones will rub together, causing pain. Due to pain in a joint, the surrounding muscle is used less, and muscle strength is thus weakened.
  • osteoarthritis The usual symptoms of osteoarthritis are stiffness, limitation of motion, pain and joint deformity and affected joints display edema, hot flashes and abnormal enlargement of joints.
  • osteoarthritis The prevalence of osteoarthritis is similar in men and women. However, in women a greater number of joints are affected, while men suffer from a higher frequency of hip joint invasion.
  • the risk factors of osteoarthritis include aging (prevalence rates increase markedly with age), obesity, congenital dysplasia of the hip, accidental or athletic trauma, a history of arthritis, drugs, particular job groups, surgery and heredity. Osteoarthritis itself does not greatly affect one's life, but chronic osteoarthritis sustaining for a long period of time causes pain and deformity of the joints and thus reduces the quality of life. In particular, osteoarthritis in the knees is known as a major cause of chronic disability.
  • osteoarthritis has been treated using anti-inflammatory substances of the corticosteroid type (such as hydrocortisone and Betamethasone), which function to inhibit prostaglandin synthesis, as well as with a large number of nonsteroidal anti-inflammatory drugs (NSAIDs, such as diclofenac, aspirin and ibuprofen), which have an analgesic as well anti-inflammatory effect.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • the invention provides the use of an A 3 adenosine receptor agonist (A 3 AR agonist) for the preparation of a pharmaceutical composition for the treatment of osteoarthritis in a mammal subject.
  • a 3 AR agonist A 3 adenosine receptor agonist
  • the present invention provides a method for the treatment of osteoarthritis in a mammal subject, the method comprises administering to said subject in need of said treatment an amount of an A 3 AR agonist, the amount being effective to treat or prevent the development of osteoarthritis.
  • the invention provides a pharmaceutical composition for the treatment of osteoarthritis in a mammal subject comprising as active ingredient an A 3 AR agonist and a pharmaceutically acceptable carrier.
  • a 3 AR agonist may be by itself, or at times in combination with other drugs such as methotrexate (MTX, steroids, NSAIDS, and others.
  • MTX methotrexate
  • steroids steroids
  • NSAIDS NSAIDS
  • FIGS. 1A-1B are bar graphs showing the effect of treatment of IB-MECA (CF101) or a combined treatment of IB-MECA and MIX on the proliferation of human fibroblasts like synoviocytes (FLS) ( FIG. 1A ) or rat FLS ( FIG. 1B ) as determined by MTT assay.
  • FIG. 2 is a graph showing the difference in diameter of MIA injected knee (Right knee) and diameter of the MIA un-injected knee (Left knee) within the same animal as a function of days after MIA induction, in CF101 treated (- ⁇ - CF101) and non treated (- ⁇ - control). Each group contained 5 animals.
  • FIGS. 3A-3D are roentgenographic images of knees showing normal tibial epiphysial line without sclerosis in CF101 treated animals ( FIGS. 3C and 3D , left and right knees respectively) as compared to vehicle treated animals ( FIGS. 3A and 3B , left and right knees, respectively).
  • FIGS. 4A-4E are Western Blot analyses of protein extracts derived from CF101 treated (CF101) and non-treated (Control) knee joints of OA rats; the protein extracts being A 3 AR ( FIG. 4A ), PI3K ( FIG. 4B ), IKK ( FIG. 4C ), NF- ⁇ B ( FIG. 4D ), GSK-3 ⁇ , ( FIG. 4E ).
  • the invention is described in the following detailed description with reference to therapeutic methods for the treatment of osteoarthritis involving administration of an A 3 AR agonist to a subject in need of same. It should be noted that in addition to said therapeutic methods, also encompassed within the present invention is the use of an A 3 AR agonist for the preparation of a pharmaceutical composition for administration to a subject suffering from osteoarthritis as well as a pharmaceutical composition for the treatment of osteoarthritis that comprises an effective amount of an A 3 AR agonist and a pharmaceutically acceptable carrier.
  • an A 3 AR agonist includes one or more agonists.
  • composition consisting essentially of an A 3 AR agonist will not include or include only insignificant amounts (amounts that will have an insignificant effect on osteoarthritis) of other active ingredients that have such an activity.
  • compositions consisting essentially of the A 3 AR agonist as defined herein would not exclude trace contaminants from the isolation and purification method, pharmaceutically acceptable carriers, such as phosphate buffered saline, excipients, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other elements. Embodiments defined by each of these transition terms are within the scope of this invention.
  • the method comprises administering to said subject an effective amount of an A 3 AR agonist.
  • treatment comprises treating osteoarthritis to reverse diseases symptoms, preventing the development of osteoarthritis, as well as managing and/or ameliorating osteoarthritis or one or more symptoms thereof.
  • treatment refers to administering a therapeutically effective amount of an A 3 AR agonist to achieve a desired therapeutic effect.
  • the desired therapeutic effect may include, without being limited thereto, improving motility of the subject, decrease in swelling and tenderness of the joints, slowing or preventing the deterioration of the joints and the surrounding tissue, slowing any irreversible damage caused by a chronic stage of osteoarthritis, increasing the time period of the remission between acute attacks of the disease, lessening of the severity of or curing osteoarthritis, or providing more rapid recovery form osteoarthritis, as well as decreasing any one of the following symptoms: stiffness, pain and joint deformity, joint edema, hot flashes and abnormal enlargement of joints or preventing the manifestation of such symptoms before they occur.
  • treatment also includes prevention of the development of osteoarthritis (e.g. in subjects having high disposition of developing the disease, such as athletes) as well as reversal of damage caused to cartilage as a result of the disease.
  • the A 3 AR agonist is any compound that is capable of specifically binding to the adenosine A 3 receptor (“A 3 R”), thereby fully or partially activating said receptor thereby yielding a therapeutic effect (in this particular case, an anti-osteoarthritic effect).
  • a 3 R adenosine A 3 receptor
  • the A 3 AR agonist is thus a molecule that exerts its prime effect through the binding and activation of the A 3 AR.
  • the A 3 AR agonist has a binding affinity (K i ) to the human A 3 AR of less than 1000 nM, desirably less than 500 nM, advantageously less 200 nM and even less than 100 nM, typically less than 50 nM, preferably less than 20 nM, more preferably less than 10 nM and ideally less than 5 nM.
  • K i binding affinity
  • a 3 AR agonists can also interact with and activate other receptors with lower affinities (namely a higher Ki).
  • a molecule will be considered an A 3 AR agonists in the context of the invention (namely a molecule that exerts its prime effect through the binding and activation A 3 R) if its affinity to the A 3 R is at least 3 times (i.e. its Ki to the A 3 R is at least 3 times lower), preferably 10 times, desirably 20 times and most preferably at least 50 times larger than the affinity to any other of the adenosine receptors.
  • the affinity of A 3 AR agonists to the human A 3 R as well as its relative affinity to the other human adenosine receptors can be determined by a number of assays, such as a binding assay.
  • binding assays include providing membranes or cells having the receptor and measuring the ability of the A 3 AR agonist to displace a bound radioactive agonist; utilizing cells that display the respective human adenosine receptor and measuring, in a functional assay, the ability of the A 3 AR agonist to activate or deactivate, as the case may be, downstream signaling events such as the effect on adenylate cyclase measured through increase or decrease of the cAMP level; etc.
  • an A 3 AR agonist is thus preferably administered at a dose such that the blood level that will be attained will give rise to essentially only A 3 R activation.
  • X 1 is R a R b NC( ⁇ O), wherein R a and R b may be the same or different and are selected from the group consisting of hydrogen, C 1 -C 10 alkyl, amino, C 1 -C 10 haloalkyl, C 1 -C 10 aminoalkyl, and C 3 -C 10 cycloalkyl;
  • R 2 is selected from the group consisting of hydrogen, halo, C 1 -C 10 alkyloxy, amino, C 2 -C 10 alkenyl, and C 2 -C 10 alkynyl;
  • R 5 is selected from the group consisting of R- and S-1-phenylethyl, an unsubstituted benzyl group, and a benzyl group substituted in one or more positions with a substituent selected from the group consisting of C 1 -C 10 alkyl, amino, halo, C 1 -C 10 haloalkyl, nitro, hydroxy, acetamido, C 1 -C 10 alkoxy, and sulfo.
  • R a and R b may be the same or different and are selected from the group consisting of hydrogen and C 1 -C 10 alkyl, particularly when R 2 is hydrogen or halo, especially hydrogen.
  • Additional specific compounds are those compounds wherein R a is hydrogen and R 2 is hydrogen, particularly when R 5 is unsubstituted benzyl.
  • R b is a C 1 -C 10 alkyl or C 3 -C 10 cycloalkyl, particularly a C 1 -C 10 alkyl, and more particularly methyl.
  • R a is hydrogen
  • R b is C 1 -C 10 alkyl or C 3 -C 10 cycloalkyl
  • R 5 is R— or S-1-phenylethyl or a benzyl substituted in one or more positions with a substituent selected from the group consisting of halo, amino, acetamido, C 1 -C 10 haloalkyl, and sulfo, where the sulfo derivative is a salt, such as a triethylammonium salt.
  • R 2 is a C 2 -C 10 alkenylene of the formula R d —C ⁇ C— where R d is a C 1 -C 8 alkyl
  • R 2 is other than hydrogen, particularly those wherein R 2 is halo, C 1 -C 10 alkylamino, or C 1 -C 10 alkylthio, and, more preferably, when additionally R a is hydrogen, R b is a C 1 -C 10 alkyl, and/or R 5 is a substituted benzyl.
  • Such specifically disclosed compounds include 2-chloro-N 6 -(3-iodobenzyl)-9-[5-(methylamido)- ⁇ -D-ribofuranosyl]-adenine, N 6 -(3-iodobenzyl)-2-methylamino-9-[5 (methylamido)- ⁇ -D-ribofuranosyl]-adenine, and N 6 -(3-iodobenzyl)-2-methylthio-9-[5-(methylamido)- ⁇ -D-ribofuranosyl]-adenine.
  • X is O
  • R 6 is R a R b NC( ⁇ O), wherein R a and R b may be the same or different and are selected from the group consisting of hydrogen, C 1 -C 10 alkyl, amino, C 1 -C 10 haloalkyl, C 1 -C 10 aminoalkyl, and C 3 -C 10 cycloalkyl;
  • R 7 and R 8 may be the same or different and are selected from the group consisting of C 1 -C 10 alkyl, R- and S-1-phenylethyl, an unsubstituted benzyl group, and a benzyl group substituted in one or more positions with a substituent selected from the group consisting of C 1 -C 10 alkyl, amino, halo, C 1 -C 10 haloalkyl, nitro, hydroxy, acetamido, C 1 -C 10 alkoxy, and sulfo; and
  • R 9 is selected from the group consisting of halo, benzyl, phenyl, and C 3 -C 10 cycloalkyl.
  • WO 99/06053 discloses in examples 19-33 compounds selected from:
  • the A 3 AR agonist is a compound that exerts its prime effect through the binding and activation of the adenosine A 3 AR and is a purine derivative falling within the scope of the general formula (I):
  • R′ and R′′ represent independently an alkyl group
  • R 16 is selected from the group consisting of heteroaryl-NR a —C(Z)-, heteroaryl-C(Z)-, alkaryl-NR a —C(Z)-, alkaryl-C(Z)-, aryl-NR—C(Z)- and aryl-C(Z)-; Z representing an oxygen, sulfur or amine; or a physiologically acceptable salt of the above compound.
  • the A 3 AR agonist is a nucleoside derivative of the general formula (IV):
  • non-cyclic carbohydrate groups e.g. alkyl, alkenyl, alkynyl, alkoxy, aralkyl, alkaryl, alkylamine, etc
  • the non-cyclic carbohydrate groups are either branched or unbranched, preferably containing from one or two to twelve carbon atoms.
  • a specific group of A3AR agonists are the N 6 -benzyladenosine-5′-uronamide derivatives.
  • Some preferred N 6 -benzyladenosine-5′-uronamide derivatives are N 6 -2-(4 aminophenyl)ethyladenosine (APNEA), N 6 -(4-amino-3-iodobenzyl) adenosine-5′-(N-methyluronamide) (AB-MECA) and 1-deoxy-1- ⁇ 6 -[( ⁇ 3-iodophenyl ⁇ methyl)amino]-9H-purine-9-yl ⁇ -N-methyl- ⁇ -D-ribofuranuronamide (IB-MECA) and 2-chloro-N 6 -(3-iodobenzyl)adenosine-5′-N-methlyuronamide (Cl—IB-MECA).
  • the A 3 AR agonist may be an oxide derivative of adenosine, such as N 6 -benzyladenosine-5′-N-alkyluronamide-N 1 -oxide or N 6 -benzyladenosine-5′-N-dialkyluronamide-N 1 -oxide, wherein the 2-purine position may be substituted with an alkoxy, amino, alkenyl, alkynyl or halogen
  • the A 3 AR agonist is administered in amounts which are sufficient to achieve an anti-osteoarthritic effect.
  • the amount of the A 3 AR agonist will depend on the severity of the disease, the intended therapeutic regiment and the desired therapeutic dose. By way of example, were the dose is 1 mg per day and the desired administration regiment is once daily administration, the amount of the A 3 AR agonist in a pharmaceutical composition comprising same will be 1 mg. Where it is intended to divide this daily dose in 2 daily administrations, the amount of the active agent in the pharmaceutical composition will be 0.5 mg.
  • an amount effective to achieve the desired effect is determined by considerations known in the art.
  • An “anti-osteoarthritic effective amount” for purposes herein must be effective to achieve a therapeutic effect, the therapeutic effect being as defined hereinbefore.
  • the effective amount depends on a variety of factors including the affinity of the chosen A 3 AR agonist to the A 3 AR, its distribution profile within the body, a variety of pharmacological parameters such as half life in the body, on undesired side effects, if any, on factors such as age and gender of the subject to be treated, etc.
  • the effective amount is typically tested in clinical studies having the aim of finding the effective dose range, the maximal tolerated dose and the optimal dose. The manner of conducting such clinical studies is well known to a person versed in the art of clinical development.
  • An amount may also at times be determined based on amounts shown to be effective in animals. It is well known that an amount of X mg/Kg administered to rats can be converted to an equivalent amount in another species (notably humans) by the use of one of possible conversions equations well known in the art. Examples of conversion equations are as follows:
  • Rat (150 g) to Man (70 Kg) is 117 the rat dose. This means that in the present case 0.001-0.4 mg/Kg in rats equals to about 0.14-56 microgram/Kg in humans; assuming an average weight of 70 Kg, this would translate into an absolute dosage of about 0.01 to about 4 mg.
  • the amounts equivalent to 0.001-0.4 mg/Kg in rats for humans are 0.16-64 ⁇ g/Kg; namely an absolute dose for a human weighing about 70 Kg of about 0.011 to about 4.4 mg, similar to the range indicated in Conversion I.
  • Another alternative for conversion is by setting the dose to yield the same plasma level or AUC as that achieved following administration to an animal.
  • mice based on measurement made in mice following oral administration of IB-MECA (an A 3 AR agonist) and based on such measurements made in humans in a clinical study in which IB-MECA was given to healthy male volunteers it was concluded that a dose of 1 microgram/Kg-400 microgram/Kg in mice in which IB-MECA was effective and is equivalent to a human dose of about 0.14-57 microgram/Kg, namely a total dose for a 70 Kg individual of 0.01-4 mg.
  • IB-MECA an A 3 AR agonist
  • a preferred dosage range for IB-MECA and Cl—IB-MECA would be less than 4 mg, typically within the range of about 0.01 to about 2 mg (about 0.14-28 micrograms/Kg, respectively) and desirably within the range of about 0.1 to 1.5 mg (about 1.4-21 micrograms/Kg, respectively). This dose may be administered once, twice or at times several times a day.
  • the administration of A 3 AR agonist is preferably daily administration, between once and a few times a day, preferably once or twice a day, the dose in each administration being in the range of between about 1 to about 1000 ⁇ g/kg body weight, preferably less than 400 ⁇ g/kg body weight, and even less than 200 ⁇ g/kg body weight
  • the dose of A 3 AR agonist is in a range of 1 to 100 ⁇ g/kg body weight.
  • composition in the context of the invention is intended to mean a combination of the active agent(s), together or separately, with a pharmaceutically acceptable carrier as well as other additives.
  • the carrier may at times have the effect of the improving the delivery or penetration of the active ingredient to the target tissue, for improving the stability of the drug, for slowing clearance rates, for imparting slow release properties, for reducing undesired side effects etc.
  • the carrier may also be a substance that stabilizes the formulation (e.g. a preservative), for providing the formulation with an edible flavor, etc.
  • stabilizers and adjuvants see E. W. Martin, REMINGTON'S PHARMACEUTICAL SCIENCES, MacK Pub Co (June, 1990).
  • pharmaceutically acceptable carrier in the context of the present invention denotes any one of inert, non-toxic materials, which do not react with the A 3 AR agonist and which can be added to formulations as diluents, carriers or to give form or consistency to the formulation.
  • composition of the present invention is administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners.
  • the choice of carrier will be determined in part by the particular active ingredient, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable pharmaceutical compositions of the present invention.
  • the A 3 AR agonist may be administered to the subject by a variety of delivery modes as known in the art. It is preferable however that the A 3 AR agonist be administered orally.
  • the carrier will be selected based on the desired form of the formulation.
  • Typical examples of carriers suitable for oral administration include (a) liquid solutions, where an effective amount of the A 3 AR agonist is dissolved in diluents, such as water, saline, natural juices, alcohols, syrups, etc.; (b) capsules (e.g.
  • the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers), tablets, lozenges (wherein the A 3 AR agonist is in a flavor, such as sucrose or the A 3 AR agonist is in an inert base, such as gelatin and glycerin), and troches, each containing a predetermined amount of A 3 AR agonist as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; (e) suitable emulsions; (f) liposome formulation; and others.
  • the A 3 AR agonist may also be formulated for topical application.
  • the A 3 AR agonist is combined with a physiologically acceptable carrier to obtain a cream, a lotion, an ointment, a gel, a hydrogel, a water-in-oil emulsion and the like, suitable for topical application, as known to those skilled in the art.
  • an A 3 AR agonist may at times be in combination with other drugs such as methotrexate (MTX), steroids, NSAIDS, and others.
  • MTX methotrexate
  • steroids steroids
  • NSAIDS NSAIDS
  • the other drug and the A 3 AR agonist may be given to patients at the same time or at different times, depending on the dosing schedule of each of the drugs.
  • MTX for example, is typically given to patients once weekly at doses ranging between 5 and 25 mg, each weekly dose, either orally or parenterally.
  • An A 3 AR agonist is typically given at a more frequent dosing schedule, for example once or twice daily.
  • CF101 alone or in combination with MTX, on the proliferation of the FLS was tested utilizing an MTT assay.
  • the cells (5 ⁇ 10 4 /ml cells) were incubated in 96-well microtiter plates for 72 hours in the growth medium. At the last 24 hours CF101 (10 nM) were added to the cultures.
  • Synovia tissue from adjuvant induced arthritis rats was collected. The tissue was minced and subjected for digestion in 4 mg/ml type I collagenase and 0.25 w/v trypsine in DMEM. The mixture was shacked vigorously for 4 hours at 37°. The released cells were separated from the supernatant by centrifugation and cultured in DMEM containing 15% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin in a 37° C., 5% CO 2 incubator. After overnight incubation the nonadherent cells were removed. The adherent cells (FLS) were sub-cultured at a 1:2 ratio, and the cells from passages 4 through 10 were used in the experiments.
  • CF101 alone or in combination with MTX, on the proliferation of the FLS was tested utilizing an MTT assay.
  • the cells (5 ⁇ 10 4 /ml cells) were incubated in 96-well microtiter plates for 72 hours in the growth medium. At the last 24 hours CF101 (10 nM) were added to the cultures.
  • FIGS. 1A and 1B show, respectively, the effect of CF101 alone, MTX alone and a combination of CF101 and MTX on the proliferation of human and rat FLS, respectively, as evaluated by the MTT assay. As shown, the percent of inhibition as compared to control was significant (20% above control). As can clearly be seen, both CF101 alone or CF101 in combination with MTX exhibited a marked inhibitory effect on the FLS.
  • MIA monoidoacetate
  • Knee diameter was measured using calibrated digital caliper adapted by reinforcing the tips for knee diameter measure.
  • the results presented in FIG. 2 show the delta between the diameter of the MIA injected knee (Right knee) and the diameter of the MIA un-injected knee (Left knee) within the same animal.
  • the group of the control is compared to the CF101 treated group (5 animals in each group).
  • FIGS. 3A-3D wherein FIGS. 3A and 3B represent the non-treated control group and FIGS. 3C and 3D represent the CF101 treated group).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
US11/632,897 2005-11-30 2006-11-29 Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment Abandoned US20080300213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74063105P 2005-11-30 2005-11-30
PCT/IL2006/001374 WO2007063538A1 (en) 2005-11-30 2006-11-29 Use of a3 adenosine receptor agonist in osteoarthritis treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/001374 A-371-Of-International WO2007063538A1 (en) 2005-11-30 2006-11-29 Use of a3 adenosine receptor agonist in osteoarthritis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/160,462 Continuation US10265337B2 (en) 2005-11-30 2016-05-20 Use of A3 adenosine receptor agonist in osteoarthritis treatment

Publications (1)

Publication Number Publication Date
US20080300213A1 true US20080300213A1 (en) 2008-12-04

Family

ID=37872156

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/632,897 Abandoned US20080300213A1 (en) 2005-11-30 2006-11-29 Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
US15/160,462 Active US10265337B2 (en) 2005-11-30 2016-05-20 Use of A3 adenosine receptor agonist in osteoarthritis treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/160,462 Active US10265337B2 (en) 2005-11-30 2016-05-20 Use of A3 adenosine receptor agonist in osteoarthritis treatment

Country Status (12)

Country Link
US (2) US20080300213A1 (da)
EP (1) EP1959939B1 (da)
JP (2) JP5339916B2 (da)
KR (1) KR101101252B1 (da)
CN (1) CN101330909B (da)
AT (1) ATE540673T1 (da)
AU (1) AU2006321165B2 (da)
BR (1) BRPI0619395A2 (da)
CA (1) CA2622879C (da)
DK (1) DK1959939T3 (da)
ES (1) ES2379591T3 (da)
WO (1) WO2007063538A1 (da)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200483A1 (en) * 2004-10-22 2008-08-21 Robin Alec Fairhurst Purine Derivatives for Use as Adenosin A-2A Receptor Agonists
US20080207648A1 (en) * 2005-01-14 2008-08-28 Robin Alec Fairhurst Organic Compounds
US20090105476A1 (en) * 2006-04-21 2009-04-23 Novartis Ag Organic Compounds
US20090281126A1 (en) * 2006-04-21 2009-11-12 Novartis Ag Organic Compounds
US20090325967A1 (en) * 2006-09-14 2009-12-31 Robin Alec Fairhurst Adenosine derivatives as a2a receptor agonists
US20100041918A1 (en) * 2006-11-10 2010-02-18 Novartis Ag Cyclopentene diol monoacetate derivatives
US20100190784A1 (en) * 2006-04-21 2010-07-29 Novartis Ag Organic Compounds
US20100286126A1 (en) * 2006-04-21 2010-11-11 Novartis Ag Organic Compounds
US8071565B2 (en) 2006-07-13 2011-12-06 Novartis Ag Purine derivatives as a2a agonists
US10441541B2 (en) * 2015-09-14 2019-10-15 New York University Methods and compositions for treating osteoarthritis and promoting cartilage formation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2137202B1 (en) 2007-03-14 2017-06-21 Can-Fite Biopharma Ltd. Process for the synthesis of ib-meca
IL184620A0 (en) * 2007-07-15 2008-01-20 Can Fite Biopharma Ltd Composition for the treatment of inflammation
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US20040167094A1 (en) * 2002-11-19 2004-08-26 Can-Fite Biopharma Ltd. A3AR agonists for the treatment of inflammatory arthritis
WO2005000331A2 (en) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
JP5001645B2 (ja) * 2004-04-02 2012-08-15 電気化学工業株式会社 ヒアルロン酸−メトトレキサート結合体
KR20070085839A (ko) * 2004-11-08 2007-08-27 캔-파이트 바이오파마 리미티드 가속 골 흡수의 치료 방법
JP2008521883A (ja) * 2004-12-02 2008-06-26 キャン−ファイト・バイオファーマ・リミテッド 炎症治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US20040167094A1 (en) * 2002-11-19 2004-08-26 Can-Fite Biopharma Ltd. A3AR agonists for the treatment of inflammatory arthritis
WO2005000331A2 (en) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gotlieb, D. (2005) Treatment of Rheumatoid Arthritis and Osteoarthritis. Retrieved [online] from the internet Retrieved on 9/25/2014. *
Sokolove, J., Lepus, C.M. (2013) Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Therapeutic Advances in Musculoskeletal Disease, vol. 5, no. 2, p. 77-94. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200483A1 (en) * 2004-10-22 2008-08-21 Robin Alec Fairhurst Purine Derivatives for Use as Adenosin A-2A Receptor Agonists
US8163754B2 (en) 2004-10-22 2012-04-24 Novartis Ag Purine derivatives for use as adenosine A-2A receptor agonists
US20080207648A1 (en) * 2005-01-14 2008-08-28 Robin Alec Fairhurst Organic Compounds
US8114877B2 (en) 2005-01-14 2012-02-14 Novartis Ag Organic compounds
US8193164B2 (en) 2006-04-21 2012-06-05 Novartis Ag Organic compounds
US20090105476A1 (en) * 2006-04-21 2009-04-23 Novartis Ag Organic Compounds
US20090281126A1 (en) * 2006-04-21 2009-11-12 Novartis Ag Organic Compounds
US8318750B2 (en) 2006-04-21 2012-11-27 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
US20100190784A1 (en) * 2006-04-21 2010-07-29 Novartis Ag Organic Compounds
US20100286126A1 (en) * 2006-04-21 2010-11-11 Novartis Ag Organic Compounds
US8071565B2 (en) 2006-07-13 2011-12-06 Novartis Ag Purine derivatives as a2a agonists
US8188100B2 (en) 2006-09-14 2012-05-29 Novartis Ag Adenosine derivatives as A2A receptor agonists
US20090325967A1 (en) * 2006-09-14 2009-12-31 Robin Alec Fairhurst Adenosine derivatives as a2a receptor agonists
US20100041918A1 (en) * 2006-11-10 2010-02-18 Novartis Ag Cyclopentene diol monoacetate derivatives
US10441541B2 (en) * 2015-09-14 2019-10-15 New York University Methods and compositions for treating osteoarthritis and promoting cartilage formation

Also Published As

Publication number Publication date
JP2009517458A (ja) 2009-04-30
CA2622879C (en) 2011-07-05
AU2006321165A1 (en) 2007-06-07
US10265337B2 (en) 2019-04-23
KR20080071609A (ko) 2008-08-04
JP5339916B2 (ja) 2013-11-13
AU2006321165B2 (en) 2010-04-22
EP1959939A1 (en) 2008-08-27
EP1959939B1 (en) 2012-01-11
ES2379591T3 (es) 2012-04-27
DK1959939T3 (da) 2012-04-23
KR101101252B1 (ko) 2012-01-04
CA2622879A1 (en) 2007-06-07
US20160263142A1 (en) 2016-09-15
ATE540673T1 (de) 2012-01-15
JP2013166789A (ja) 2013-08-29
BRPI0619395A2 (pt) 2011-10-04
CN101330909B (zh) 2012-09-26
CN101330909A (zh) 2008-12-24
WO2007063538A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
US10265337B2 (en) Use of A3 adenosine receptor agonist in osteoarthritis treatment
EP1817079B1 (en) Treatment of inflammation
WO2006011130A1 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome
EP1699459B1 (en) Method for treatment of multiple sclerosis
US20080051364A1 (en) Therapeutic Treatment of Accelerated Bone Resorption
KR20090032083A (ko) 신장 기능이 손상된 개체의 이뇨 작용 개선 방법
KR20080090517A (ko) 건성안 장애의 치료를 위한 아데노신 ａ3 수용체 길항제
US20040167094A1 (en) A3AR agonists for the treatment of inflammatory arthritis
EP1811982A1 (en) Therapeutic treatment of accelerated bone resorption
US20080051365A1 (en) Treatment of Inflammation
US9549943B2 (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
MX2008009506A (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: CAN-FITE BIOPHARMA LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FISHMAN, PNINA;REEL/FRAME:018945/0860

Effective date: 20061210

AS Assignment

Owner name: CAN-FITE BIOPHARMA LTD., ISRAEL

Free format text: CORRECTED COVER SHEET TO CORRECT THE EXECUTION DATE, PREVIOUSLY RECORDED AT REEL/FRAME (ASSIGNMENT OF ASSIGNOR'S INTEREST);ASSIGNOR:FISHMAN, PNINA;REEL/FRAME:018945/0912

Effective date: 20061210

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION